WallStreetZenWallStreetZen

NASDAQ: IRON
Disc Medicine Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IRON

Based on 7 analysts offering 12 month price targets for Disc Medicine Inc

Min Forecast
$79.00-0.95%
Avg Forecast
$95.71+20%
Max Forecast
$125.00+56.72%

Should I buy or sell IRON stock?

Based on 7 analysts offering ratings for Disc Medicine Inc.

Strong Buy
Strong Buy
5 analysts 71.43%
Buy
2 analysts 28.57%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IRON's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IRON as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their IRON stock forecasts and price targets.

IRON stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-16Find Out Why
lockedlocked$00.00+00.00%2026-06-10
lockedlocked$00.00+00.00%2026-03-02Find Out Why
lockedlocked$00.00+00.00%2026-02-27
lockedlocked$00.00+00.00%2026-02-17
Cantor Fitzgerald
Top 3%
98
Strong BuyMaintains$125.00+56.72%2026-02-17
BMO Capital
Top 23%
78
BuyMaintains$100.00+25.38%2026-02-17

1 of 1

Forecast return on equity

Is IRON forecast to generate an efficient return?

Company
-15.07%
Industry
92.73%
Market
172.49%
IRON's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IRON forecast to generate an efficient return on assets?

Company
-13.83%
Industry
27.45%
IRON is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IRON earnings per share forecast

What is IRON's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$7.34
Avg 2 year Forecast
-$7.77
Avg 3 year Forecast
-$6.15

IRON revenue forecast

What is IRON's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$32.9M
Avg 3 year Forecast
$145.1M

IRON vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IRON$79.76$95.71+20.00%Strong Buy
TARS$70.55$94.33+33.71%Strong Buy
VERA$42.96$89.75+108.92%Strong Buy
ELVN$50.92$65.40+28.44%Strong Buy
CLDX$39.93$48.50+21.46%Strong Buy
View Top Biotech Stocks

Disc Medicine Stock Forecast FAQ

Is Disc Medicine Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: IRON) stock is to Strong Buy IRON stock.

Out of 7 analysts, 5 (71.43%) are recommending IRON as a Strong Buy, 2 (28.57%) are recommending IRON as a Buy, 0 (0%) are recommending IRON as a Hold, 0 (0%) are recommending IRON as a Sell, and 0 (0%) are recommending IRON as a Strong Sell.

If you're new to stock investing, here's how to buy Disc Medicine stock.

What is IRON's earnings growth forecast for 2026-2028?

(NASDAQ: IRON) Disc Medicine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.51%.

Disc Medicine's earnings in 2026 is -$241,603,000.On average, 14 Wall Street analysts forecast IRON's earnings for 2026 to be -$280,457,711, with the lowest IRON earnings forecast at -$320,070,167, and the highest IRON earnings forecast at -$260,307,692. On average, 14 Wall Street analysts forecast IRON's earnings for 2027 to be -$296,703,784, with the lowest IRON earnings forecast at -$335,792,912, and the highest IRON earnings forecast at -$237,846,628.

In 2028, IRON is forecast to generate -$234,909,118 in earnings, with the lowest earnings forecast at -$304,721,773 and the highest earnings forecast at -$182,496,148.

What is IRON's revenue growth forecast for 2026-2028?

(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.95%.

Disc Medicine's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast IRON's revenue for 2026 to be $0, with the lowest IRON revenue forecast at $0, and the highest IRON revenue forecast at $0. On average, 14 Wall Street analysts forecast IRON's revenue for 2027 to be $1,256,024,245, with the lowest IRON revenue forecast at $231,944,868, and the highest IRON revenue forecast at $3,248,832,519.

In 2028, IRON is forecast to generate $5,541,159,850 in revenue, with the lowest revenue forecast at $1,942,882,065 and the highest revenue forecast at $8,282,708,468.

What is IRON's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IRON) forecast ROA is -13.83%, which is lower than the forecast US Biotechnology industry average of 27.45%.

What is IRON's Price Target?

According to 7 Wall Street analysts that have issued a 1 year IRON price target, the average IRON price target is $95.71, with the highest IRON stock price forecast at $125.00 and the lowest IRON stock price forecast at $79.00.

On average, Wall Street analysts predict that Disc Medicine's share price could reach $95.71 by Jun 16, 2027. The average Disc Medicine stock price prediction forecasts a potential upside of 20% from the current IRON share price of $79.76.

What is IRON's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IRON) Disc Medicine's current Earnings Per Share (EPS) is -$6.62. On average, analysts forecast that IRON's EPS will be -$7.34 for 2026, with the lowest EPS forecast at -$8.38, and the highest EPS forecast at -$6.81. On average, analysts forecast that IRON's EPS will be -$7.77 for 2027, with the lowest EPS forecast at -$8.79, and the highest EPS forecast at -$6.23. In 2028, IRON's EPS is forecast to hit -$6.15 (min: -$7.98, max: -$4.78).

What is IRON's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IRON) forecast ROE is -15.07%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.